In a separate analysis of serum and BALF of 13 patients with CIP after PD-1/PD-L1 therapy for NSCLC, elevation in both IL-17A and IL-35 was observed in both compartments (113). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.